09 November 2023 – Congratulations to ARS Pharmaceuticals on their recent four oral presentations at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting. PLC has supported ARS with neffy’s clinical development and Regulatory filings from inception and continues to support Regulatory and clinical trial work in the US and other countries.
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
- Data to be presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting.
- Supports neffy’s potential to be a safe and effective option across patient sub-populations based on data including the relationship between BMI/body weight and epinephrine exposure, congestion/rhinitis during upper respiratory tract infections, and pediatrics.